Related Experiment Videos
Non-high-density lipoprotein cholesterol: why lower is better.
Rahul Garg1, Chandrasekhar R Vasamreddy, Roger S Blumenthal
1Johns Hopkins Ciccarone Preventive Cardiology Center, Division of Cardiology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Preventive Cardiology
|July 22, 2005
Summary
Lowering non-high-density lipoprotein cholesterol (non-HDL-C) offers clinical benefits, similar to low-density lipoprotein cholesterol (LDL-C). Statins effectively reduce both, with greater LDL-C reduction leading to greater non-HDL-C reduction.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Recent trials suggest lower low-density lipoprotein cholesterol (LDL-C) levels (<100 mg/dL) provide additional clinical benefit.
- Non-high-density lipoprotein cholesterol (non-HDL-C) is a more comprehensive measure of atherogenic cholesterol particles than LDL-C.
Purpose of the Study:
- To evaluate the principle that "lower is better" applies to non-HDL-C levels.
- To assess the role of non-HDL-C as a secondary therapeutic target in patients with high triglycerides.
- To examine the correlation between non-HDL-C, small dense LDL, and apolipoprotein B.
Main Methods:
- Comparative trials of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins).
- Analysis of lipid profiles, including LDL-C and non-HDL-C levels.
- Correlation analysis with cardiovascular disease risk predictors.
Main Results:
- Statins significantly reduce both LDL-C and non-HDL-C levels.
- A direct relationship exists between the degree of LDL-C reduction and non-HDL-C reduction.
- Non-HDL-C is strongly correlated with small dense LDL and apolipoprotein B.
Conclusions:
- The "lower is better" principle is applicable to non-HDL-C reduction.
- Statins are effective in lowering non-HDL-C, making it a valuable secondary therapeutic target.
- Lowering non-HDL-C may offer additional cardiovascular risk reduction benefits.